Bard1 Life Sciences Limited (BD1:ASX)


right-arrow Created with Sketch. -0.03 (-2.75%)
MCAP $100.2M
Last trade 15.57pm 19/10/2021 20mins delayed

Latest Announcements

11/10/2021BD1Bard1 Life Sciences Limited
01/10/2021BD1Bard1 Life Sciences Limited
29/09/2021BD1Bard1 Life Sciences Limited
16/09/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
07/09/2021BD1Bard1 Life Sciences Limited
31/08/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
27/08/2021BD1Bard1 Life Sciences Limited
27/08/2021BD1Bard1 Life Sciences Limited

Company Overview

BARD1 Life Sciences Limited is an Australia-based medical diagnostics company. The Company is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.

BD1 in the news

BARD1 Life Sciences (BD1) appoints Greg Rice as chief scientific officer (CSO)…
BARD1 Life Sciences (BD1) demonstrates its test can detect a biomarker for…
BARD1 Life Sciences (BD1) advances sales, business development and commercialisation activities over…
The University of Queensland (UQ) unveils “promising” results for a potential ovarian…

Search Previous Announcements